Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maxing Xiongting Mixture for COPD with hypoxic pulmonary hypertension
ChiCTR2300076932Phase 2Recruiting
- Sponsor
- Chongqing Traditional Chinese Medicine Hospital
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Maxing Xiongting Mixture in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) (2 arms), sponsored by Chongqing Traditional Chinese Medicine Hospital. Primary endpoint: Pulmonary artery systolic pressure. Started Jan 2022; status: recruiting.
02
Drugs
Maxing Xiongting Mixture
03
Conditions
chronic obstructive pulmonary disease (COPD)pulmonary hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2300076932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076932.